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BACKGROUND: Medications that may increase risk of
birth defects if used during pregnancy or immediately
preconception are dispensed to approximately half of
female Veterans who fill prescriptions at a VA pharmacy.
OBJECTIVE: To assess receipt of counseling about risk
of medication-induced birth defects among female
Veterans of reproductive age and to examine Veterans’
confidence that their healthcare provider would counsel
them about teratogenic risks.
DESIGN AND PARTICIPANTS: Cross-sectional analysis
of data provided by 286 female Veterans of Operation
Iraqi Freedom and/or Operation Enduring Freedom
who completed a mailed survey between July 2008
and October 2010.
MAIN MEASURES: We examined associations between
demographic, reproductive, and health service utiliza-
tion variables and female Veterans' receipt of counsel-
ing and confidence that they would receive such
counseling.
KEY RESULTS: The response rate was 11 %; the large
majority (89 %) of responding female Veterans reported
use of a prescription medication in the last 12 months.
Most (90 %) of the 286 female Veterans who reported
medication use were confident that they would be told
by their healthcare provider if a medication might cause
a birth defect. However, only 24 % of women who
received prescription medications reported they had
been warned of teratogenic risks. Female Veterans who
used medications that are known to be teratogenic were
not more likely than women using other medications to
report having been warned about risks of medication-
induced birth defects, and fewer were confident that
their health care providers would provide teratogenic
risk counseling when needed.
CONCLUSIONS: Female Veterans may not receive ap-
propriate counseling when medications that can cause
birth defects are prescribed.
KEY WORDS: preconception care; contraceptive counseling; birth
defects; veterans; women’s health.
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B irth defects are a leading cause of infant mortality.
1
Each year, an estimated 120,000 US infants suffer from
birth defects2 and require billions of dollars in health care.3
Although the causes of most birth defects are unknown, some
medications have been identified as increasing risk of birth
defects. In the United States, women of reproductive age
receive an estimated 12 million prescriptions for potentially
teratogenic medications each year.4
While the US Department of Veterans Affairs (VA) has
historically served a predominantly male population, the
number of female Veterans enrolled in the VA health care
system has been growing rapidly. Between 1999 and 2006,
the number of women served by the Veterans Health
Administration (VHA) more than doubled. Currently, there
are approximately 337,000 female Veterans using VHA care
on an annual basis, and the number of women in the
military continues to increase. As two thirds of female
Veterans returning from Operation Enduring Freedom(OEF)
and Operation Iraqi Freedom (OIF) were under 30 years of
age, the VA Healthcare system is caring for a growing
number of women of childbearing age.5
Given the higher burden of comorbid conditions in
female Veterans compared to women seen in other settings,6
female Veterans are more likely to be dispensed potentially
teratogenic medications. It is estimated that half of fertile
female Veterans who receive prescriptions from a VA
pharmacy fill a prescription for a potentially teratogenic
medication each year.7 For example, each year, VA
pharmacies dispense potentially teratogenic psychiatric
medications to over 20,000 female Veterans of reproductive
age, a statin is dispensed to close to 9,000 female Veterans,
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and an angiotensin converting enzyme (ACE) inhibitor or
“angiotensin receptor blockers” (ARB) is dispensed to over
6,000 female Veterans.7
Nationally, it is estimated that fewer than 50 % of women
using potentially teratogenic medications receive contracep-
tive counseling during ambulatory care visits.4,6 As a result,
approximately 6 % of US pregnancies are exposed to
potentially teratogenic medications.8,9 As little is known
about how VA clinicians counsel their patients about the
risks of medication-induced birth defects, the goal of this
study is to evaluate the prevalence of receipt of counseling
about teratogenic risks among female Veterans, and to
assess female Veterans’ confidence that their healthcare
providers would tell them if a medication they were taking
might cause a birth defect.
METHODS
The data used for this study was collected as part of a larger
research study, the Women Veterans Cohort Study (WVCS).10
WVCS is a two-phase longitudinal study examining health-
care utilization, health outcomes, and costs of care among a
cohort of OEF/OIF male and female veterans in VA care. The
sampling frame for the overall study is the OEF/OIF roster,
provided to the VA by the Department of Defense Manpower
Data Center’s (DMDC) Contingency Tracking System. The
OEF/OIF roster is a database of veterans who separated from
OEF/OIF military service and enrolled in VA healthcare
between October 1, 2001 and April 30, 2010 (N=749,036 of
whom 88,166 are women). Roster information includes
veterans’ sex, race, date of birth, deployment dates, armed
forces branch (Army, Navy, Air Force, Marines, or Coast Guard)
and component (National Guard, Reserve or active duty).
This paper utilizes data from the second phase (prospective
survey component) of WVCS. OEF/OIF veterans who were
enrolled for care in the New England Region or Indiana were
invited to participate in this prospective study. These regions
were selected as a matter of convenience, as funding
constraints precluded the study of more regions. Thus, letters
were sent to 3,251 female OEF/OIF veterans. Veterans
expressing interest in the study, that is those who “opted
in,” either met with or called the research coordinator, who
provided a detailed description of the study, which would
involve completion of three surveys over the course of
2 years, and screened for eligibility criteria including the
ability to speak and read English, and participation in OEF or
OIF. Those who agreed to participate were given an
appointment at which they provided signed informed consent
and completed the baseline survey, which was the source of
data for these analyses. This survey was developed and pilot-
tested by the WVCS investigators. Between July 2008 and
October 2011, baseline surveys were completed by 11 % of
female Veterans who were invited to participate (n=365). For
the purposes of this analysis, we excluded Veterans over
50 years of age (n=27) and those using post-menopausal
hormone therapy (n=16), producing a sample of 322 female
premenopausal Veterans. For analyses regarding receipt of
counseling about risks of medication-induced birth defects,
we further excluded 36 women who had not used prescrip-
tion medication in the last 12 months.
All medication data was self-reported; no data was
drawn from VA medical or pharmacy records. Specifically,
female Veterans were asked “Have you taken any
prescription medications in the past 12 months? (yes/
no),” and then were asked about use of multiple different
classes of medications. Veterans were asked about use of a
number of potentially teratogenic medications, which
included those most commonly used: benzodiazepines,
statins, and antihypertensive medications. For example,
Veterans were asked whether they had taken a “Benzodi-
azepine such as Diazepam (Valium), Lorazepam (Ativan),
Clonazepam (Klonopin), or Alprazolam (Xanax),” or a
“Statin such as Lovastatin (Mevacor). Simvastatin (Zocor),
Atorvastatin (Lipitor), Pravastatin (Pravachol), Rosuvasta-
tin (Crestor), or Fluvastatin (Lescol).” Similarly, Veterans
were asked if they had “taken an angiotensin converting
enzyme (ACE) inhibitor such as lisinopril (Zestril, Prinivil),
Enalapril (Vasotec), Captopril (Capoten),”and/or “angioten-
sin receptor blockers (ARBs) such as losartan (Cozaar),
Irbesartan (Avapro), Valsartan (Diovan).” Unfortunately, data
was not collected on use of anti-epileptic medications, or
other commonly used potentially teratogenic medications.
Female Veterans were then asked, “when your healthcare
provider prescribed the medications listed above, did he/she
tell you if these medications had any chance of causing a
birth defect? (yes/no),” and “How confident are you that your
healthcare provider would tell you if a medication you are
taking might cause a birth defect?” Response options
included: very confident, moderately confident, neither
confident nor unconfident, moderately unconfident, and very
unconfident; we dichotomized these responses by consider-
ing Veterans to have felt “confident” in receipt of this
counseling if they reported they were very confident,
moderately confident, neither confident or unconfident, or
“unconfident” if they reported feeling either moderately or
very unconfident, in order to most conservatively estimate
the number of women Veterans who lack confidence that
they will receive desired counseling.
Details of women’s reproductive health history were
collected, including whether the Veteran was sexually
active, had ever been pregnant, whether pregnancies had
been planned, whether pregnancies resulted in abortion or
birth, and whether any of the Veteran’s children had been
affected by birth defects. In addition, Veterans were asked,
“Were any of the pregnancies the result of sexual assault or
abuse while in the military? (yes/no)” Veterans were asked
whether they had a history of infertility and whether they
had used condoms with last sex. Veterans’ recent use of
hormonal contraception was self-reported; Veterans were
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asked, “During the past 12 months, have you taken
prescription medicine for birth control?” In addition,
Veterans were asked, “While in the military, did you ever
have problems getting the birth control that you needed?
(yes/no).”
Data were also collected on Veterans’ sociodemographic
characteristics, self-reported health history, including sub-
stance abuse, and health services use. Specifically, the
survey asked whether the Veteran received healthcare from
the VA only, non-VA providers only, or received both VA
and non-VA care, and whether the veteran had received care
from a VA women’s health clinic. Veterans were asked
whether they agreed or disagreed with the statement, “The
VA has good, quality health care.” Finally, Veterans were
asked, “Do you plan to use the VA Healthcare system in the
future?” and provided with the following response options:
yes, as a primary source of care, as a back up to non-VA
care, for prescriptions only, and no.
We tabulated responses to each of these questions and
then used chi-square tests, or Fischer’s exact tests when
appropriate, to examine whether female Veterans’ receipt of
teratogenic risk counseling varied by the Veteran’s socio-
demographic characteristics, health history, or where the
Veteran received healthcare. In addition, we examined
whether receipt of such counseling was associated with
Veterans’ recent use of hormonal contraception. Finally, we
examined the relationship between women’s use of poten-
tially teratogenic medications in the last year and their
confidence that they would be counseled about teratogenic
risks. All analyses were done using SAS version 9.1 (SAS
Institute, Cary, NC); a priori, p<0.05 was considered
statistically significant. The study was approved by the
institutional review boards of the VA Connecticut and Yale
University.
RESULTS
Of the 322 premenopausal female Veterans who completed
surveys, 286 (89 %) female Veterans reported use of a
prescription medication in the last 12 months. The mean age
of these Veterans was 30.2 years; other sociodemographic
characteristics of these Veterans are shown in Table 1.
Most (88 %) of these female Veterans were sexually
active. Less than half (48%) of participating Veterans reported
use of prescription contraception in the last 12 months
(Table 2).
Only 24 % of participating Veterans reported they had
been told by a healthcare provider if their medications had
any chance of causing birth defects. Receipt of teratogenic
risk counseling by female Veterans was similar whether the
Veteran received care within or outside the VA system, and
whether the veteran had visited a VA women’s clinic
(Table 1). Receipt of counseling about risk of medication-
induced birth defects did not vary by education, race,
marital status (Table 1), or reproductive history (Table 2).
Women who used potentially teratogenic medications, such
as an ACE-inhibitor or ARB, were not more likely to be
warned about the risk of medication-induced birth defects,
and in fact, tended to be less likely to receive such
counseling, than women who used other medications
(Table 3). Women who had been counseled about terato-
genic risks tended to be more likely to use prescription
contraception (56 % vs 46 %, p=0.16), but this finding did
not reach statistical significance.
The majority of female Veterans were confident that they
would be told by their healthcare provider if a medication
Table 1. Sociodemographic Characteristics of Participating
Female Veterans, By Self-Reported Receipt of Counseling About










73 (25) 16 (22) 56 (77)
Some college or
Associates degree
69 (24) 17 (25) 51 (74)
College degree 108 (38) 25 (23) 83 (77)
Graduate or
professional degree




239 (84) 56 (23) 182 (76)
Black, not Hispanic/
Latino
17 (6) 4 (24) 13 (76)
Hispanic/Latino 25 (9) 7 (28) 17 (68)
Asian or Pacific
Islander
5 (2) 1 (20) 4 (80)
Married 116 (41) 32 (28) 83 (72) 0.41
Divorced 55 (19) 15 (27) 40 (73)
Separated 5 (2) 1 (20) 4 (80)
Widowed 4 (1) 0 (0) 4 (100)
Single 106 (37) 20 (19) 85 (80)
Living alone 64 (22) 15 (23) 48 (75) 0.98
With husband 106 (48) 27 (25) 78 (74) 0.78
With male partner or
boyfriend
30 (14) 5 (17) 25 (83) 0.78
Annual income (own) 0.33
< $25,000 107 (37) 26 (25) 79 (75)
$25,001 – $50,000 92 (32) 15 (16) 77 (84)
$50,001 – $75,000 52 (18) 17 (33) 35 (67)
$75,001 – $100,000 25 (9) 8 (32) 17 (68)
$100,001 – $150,000 6 (2) 2 (33) 4 (67)
Refused/Don’t know 4 (2) 0 (0) 4 (100)
Current Private Health
Insurance
160 (56) 36 (23) 124 (78) 0.52
Health Care from 0.42
Only from VA
providers
47 (17) 14 (30) 32 (68)
Only from non-VA
providers
45 (17) 9 (20) 36 (80)
Both VA and non-VA
providers
186 (67) 41 (22) 144 (77)
VA Women’s Center
patient
37 (32) 7 (19) 30 (81) 0.43
*We excluded from these analyses data from female veterans over
50 years of age, those who were using postmenopausal hormone
therapy, and female veterans who had not used prescription
medication in the last 12 months
†From chi-squared tests, or Fisher’s exact tests for overall differences
in receipt of counseling by groups
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they were prescribed might cause a birth defect (41 % very
confident, 29 % moderately confident, 19 % neither
confident/unconfident). Only 7 % reported they were
moderately unconfident, while 4 % were very unconfident
that they would be counseled about teratogenic risks.
However, women who had recently used a medication
labeled by the FDA as potentially teratogenic were less
confident that they would be counseled about teratogenic
risks (Table 3). For example, confidence that they would
receive teratogenic risk counseling was lower among the
four women who reported use of an ACE-inhibitor or ARB
than among women who were not using one of these
medications (50 % vs 90 %, p=0.05).
Veterans’ confidence that they would receive teratogenic
risk counseling was not significantly associated with their
sociodemographic characteristics. However, female Veter-
ans were less likely to report confidence that they would
receive teratogenic risk counseling if they had difficulty
obtaining birth control while in the military (78 % vs 91 %,
p=0.04). Similarly, the 2.1 % of female Veterans (n=6) who
reported they had become pregnant as the result of military
sexual trauma were less confident they would receive such
counseling (67 % vs 91 %, p=0.05). Veterans were also less
confident they would receive such counseling if they had a
history of drug use (e.g. marijuana (75 % vs 91 %, p=0.02),
alcohol (81 % vs 91 %, p=0.04), or “tranquilizers or ‘nerve
pills’ such as benzodiazepines without a doctor’s prescrip-
tion” (71 % vs 91 %, p=0.006)). In contrast, Veterans were
more confident that they would be informed of teratogenic
risks if they had previously had a pregnancy affected by
birth defects.
Veterans who were confident that they would receive
teratogenic risk counseling were more likely to agree with
the statement that the “VA provides good quality health-
care,” p=0.04, and to indicate that they planned to use the
VA as a primary source of healthcare in the future (85 % vs
94 %, p=0.04).
DISCUSSION
We found that only a quarter of young female Veterans
reported that their healthcare provider had warned them of
teratogenic risks with medication use. This is concerning, as
half the study participants reported no use of contraception,
and thus may be at risk of unintended pregnancy. Given the
relatively small size of this study, all associations identified
should be viewed primarily as hypothesis-generating.
However, as prior studies have found that half of female
Veterans are dispensed potentially teratogenic medications,7
these findings indicate that need for ongoing efforts to ensure
that female Veterans receive appropriate counseling when they
are prescribed medications that can cause birth defects.
Although the VA has only recently expanded its focus to
include female Veterans, outside the VA this issue requires
similar attention, as studies from multiple clinical settings have
found that women of childbearing potentially are frequently
prescribed potentially teratogenic medications.4,6,11,12
In order to help women optimize their health before
pregnancy, comprehensive preconception counseling must
include information about medication risks, alternative
treatments that may be considered if pregnancy is desired,
and effective methods of contraception if pregnancy is not
desired. Unfortunately, many primary care physicians have
limited knowledge of both teratogenic risks13 and rates of
unintended pregnancy14; thus, ensuring that women receive
teratogenic risk counseling may require ongoing clinician
Table 2. Reproductive Characteristics of Participating Female
Veterans, By Self-Reported Receipt of Counseling About Risk of










Sexually active 245 (86) 62 (25) 183 (74) 0.15
Prior pregnancy 173 (63) 44 (25) 129 (75) 0.27
Unintended
pregnancy
126 (72) 32 (25) 94 (75) 0.61
Prior abortion 51 (29) 12 (24) 39 (76) 0.58
Prior birth 114 (66) 30 (26) 84 (74) 0.96
Prior birth defect 10 (6) 3 (30) 7 (70) 0.79




61 (22) 9 (15) 52 (85) 0.06
Hormonal method
in last 12 months
136 (48) 38 (28) 98 (72) 0.16
*We excluded from these analyses data from female veterans over
50 years of age, veterans using postmenopausal hormone therapy, or
veterans who had not used a prescription medication in the last
12 months
†Infertility measured as ever tried to become pregnant for >12 months
‡From chi-squared tests and Fisher’s exact tests, when appropriate
Table 3. Self-Reported Receipt of Counseling about Risks of







Any medication (n=286) 24 % 90 %
Specific class D or X*medications:
Angiotensin converting enzyme
inhibitor or angiotensin receptor
blocker (n=4) 0 % 50 %
Benzodiazepine (n=37) 22 % 81 %
Statin (n=16) 19 % 81 %
*The US Food and Drug Administration (FDA) labels medications
using five categories. Class A and B medications are those for which
there is no evidence of fetal harm in humans. Class C designates drugs
for which adequate studies are not available. Classes D and X are
used to identify potentially teratogenic medications. Specifically, class
D medications are those for which there is evidence of fetal risk, but
“the potential benefits from the use of the drug in pregnant women
may be acceptable despite its potential risks;” class X medications are
“contraindicated in women who are or may become pregnant”
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education. Currently, the VA is addressing this challenge by
offering clinicians “mini-residencies” in Women’s Health.
Educational efforts modeled after those that have success-
fully encouraged clinicians to screen for depression15,16
may also be useful. Clinical decision support has been
proposed as a way to alert clinicians to the need for
teratogenic risk counseling,17 but refinement and evaluation
of such decision support systems remain needed. Involving
pharmacists in efforts to notify women about medication
risks may also be of benefit. However, prior efforts to use
laboratory and ultrasound data to alert dispensing pharma-
cists to pregnancies had unacceptably high rates of
misidentification of ongoing pregnancy.18 In addition,
women have indicated that they prefer to discuss plans for
pregnancy with their primary care provider in the privacy of
the clinic, rather than in pharmacy settings.19 Thus, if
pharmacists are to be involved in providing reproductive
health counseling, attention must be given to ensuring
patient privacy for discussions in pharmacies or other
clinical settings.
Although the large majority of female Veterans trusted
that their health care providers would provide them with
information about teratogenic risks, Veterans who had
received medications that were labeled as potentially
teratogenic, such as ACE-I and ARB, without discussing
these risks with their prescribing clinician had less
confidence in their healthcare providers. Similarly, women
who had ever had difficulties accessing desired services
(e.g., contraception) in the military were less likely to trust
they would receive counseling about teratogenic risks.
Patients’ trust in their healthcare providers is important
for many reasons.20–23 For example, trust in healthcare
providers has been associated with adherence to therapeutic
regimens,24 receipt of needed services,25 and health out-
comes.26 Thus, appropriately alerting female patients to
teratogenic risks can be seen as part of the larger mission of
earning our patients trust in order to effectively work with
them to improve health outcomes.
Limitations of this study include the relatively small sample
size and limited response rate. We conducted multiple
comparisons, which may increase the chance of type 1 error;
thus, none of our findings should be considered definitive, but
rather as hypothesis-generating. We have no information on
the ways Veterans who responded to this survey may differ
from those who did not; however, this study population was
more educated, and included fewer Black Veterans than
nationally representative samples, which are 30 % Black.7
As WVCS did not ask women about their use of all
potentially teratogenic medications, it is not possible to
estimate whether women in this sample were more or less
likely to use potentially teratogenic medications than the
average female Veteran. In addition, we have no data on the
quality, timing or content of the counseling Veterans received
about risks of medication-induced birth defects. Veterans’
responses to the question about how confident they were that
they would receive teratogenic risk counseling when needed
may have been affected by the survey’s first asking whether
women had received such counseling.
Nonetheless, relatively few women Veterans reported they
had been told their medications had any chance of causing a
birth defect. Thus, these findings support other recent work17
in indicating that efforts remain needed to ensure that all
women receive appropriate counseling when medications
that can cause birth defects are prescribed. Recent changes in
VA women’s healthcare, such as the implementation of
comprehensive primary care to eliminate fragmentation and
gaps in women Veterans’ care, efforts to educate VA primary
care providers in basic women’s health, including precon-
ception care, through Women’s Health Mini-Residencies,
development of a preconception care template, and multiple
educational conferences have all been designed to ensure the
VA provides women Veterans the best possible care. Private
sector health care providers should join VA providers in
striving to meet these new national standards for provision of
comprehensive Women’s Health care.
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